ProForma 2.0
validated simple linear
GRVPR
GRVPR
Aliases: GRVPR
Normalized sequence
GRVPR
5 amino acids
Release PepDiana-V1-20260620
12
Activity records
1
Source papers
10
Positive
2
Negative / threshold
Versioned scientific descriptors
No separate physicochemical property was reported in the primary-literature identity record. PepDiana release values are shown as computed properties.
Molecular weight
583.6842 Da
Molecular formula
C24H45N11O6
Theoretical pI
12
Net charge at pH 7
1.7601
GRAVY
-1.36
Instability index
31.44
Aromaticity
0
Topological polar surface area
294.73 Ų
cLogP
-3.3424
Hydrogen-bond donors
11
Hydrogen-bond acceptors
8
Rotatable bonds
17
Method: PepDiana sequence/structure descriptor pipeline
Tool: Biopython+RDKit · Biopython 1.85; RDKit 2024.09.6
Calculated: 2026-06-20T11:01:38.358971+00:00
Assumptions: ph=7; termini=free N-terminus and free C-terminus for simple linear peptides; stereochemistry=standard L-amino acids; smiles_length_limit=200
ProForma 2.0
validated simple linear
GRVPR
HELM 2.0
validated simple linear
PEPTIDE1{G.R.V.P.R}$$$$V2.0
Canonical SMILES
validated
CC(C)C(NC(=O)C(CCCNC(=N)N)NC(=O)CN)C(=O)N1CCCC1C(=O)NC(CCCNC(=N)N)C(=O)O
Isomeric SMILES
validated
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
Paper-level observations
pretreatment with tuna peptides S1, S5, S6, and S7 significantly restored viability, with S6 and S7 exhibiting efficacy comparable to the positive drug (p < 0.001) (Figure 1B).
pretreatment with S1, S5, S6, and S7 significantly reduced ROS levels in a concentration-dependent manner. (Figure 2A,B)
In comparison to the model group, all tuna peptide treatment groups at a concentration of 200 μM demonstrated enhanced cellular antioxidant capacity... (Figure 3)
treatment with tuna peptides S1, S5, S6, and S7, resulted in a significant reduction in green fluorescence and a notable increase in red fluorescence (p < 0.001)... (Figure 6)
pretreatment with 200 μM tuna peptides S1, S5, S6, and S7 significantly increased Nrf2 mRNA expression and decreased Keap1 mRNA expression in MLE-12 cells compared to the model group. (Figure 8)
At a concentration of 200 μM, the nuclear Nrf2 levels in the S1 and S6 peptide-treated groups showed significant higher compared to the model group (p < 0.05). (Figure 9)
tuna peptide S6 demonstrated the strongest anti-inflammatory effect... At a concentration of 200 μM, the tuna peptide treatment groups (S1, S6, and S7) showed a significant reduction in these inflammatory markers compared to the model group. (Figure 4)
treatment with 200 µM tuna peptides S1, S5, S6, and S7 significantly reduced p65 mRNA expression and increased IκBα mRNA expression (p < 0.001). (Figure 11A,B)
Among these, the 200 µM concentration of peptide S6 exhibited a stronger inhibitory effect on CSE-induced apoptosis in MLE-12 cells. (Figure 5)
pretreatment with 200 μM tuna peptides S1, S5, S6, and S7 significantly increased the Bcl-2/Bax mRNA expression ratio compared to the model group, with highly significant differences (p < 0.001). (Figure 11C)
To assess the safety of tuna peptides, cells were treated with 200 µM of peptide S1–8, which maintained viability above 90%... (Figure 1B).
tuna peptides S1, S5, S6, and S7 significantly promote the migration of MLE-12 cells and accelerate wound closure in a concentration-dependent manner. (Figure 7)
Citation and release provenance
Cite this identity as PepDiana record PEPDIA-PLP-001112, release PepDiana-V1-20260620. Experimental observations retain their paper, mention, and activity-record identifiers.
Record updated: 2026-06-22T07:14:26.229247+00:00